Pharmacogenetics of testosterone replacement therapy

Pharmacogenomics

Volumn 10, Issue 8, 2009, Pages 1341-1349

  Zitzmann, Michael ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Androgen receptor; Male hypogonadism; Pharmacogenetics; Testosterone

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BOLDENONE UNDECENOATE; FINASTERIDE; FLUTAMIDE;

ANDROGEN THERAPY; DNA POLYMORPHISM; EXON; GENE ACTIVITY; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE MUTATION; GENE NUMBER; GENE TARGETING; HORMONE ACTION; HUMAN; HYPOGONADISM; MALE INFERTILITY; PHARMACOGENOMICS; PHENOTYPE; PROSTATE CANCER; REVIEW; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION;

ANIMALS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MUTATION; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, ANDROGEN; TESTOSTERONE; TRINUCLEOTIDE REPEATS;

EID: 70649091213     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.58     Document Type: Review

References (53)

1. Kelleher S, Conway AJ, Handelsman DJ: Blood testosterone threshold for androgen deficiency symptoms. J. Clin. Endocrinol. Metab. 89, 3813-3817 (2004). (Pubitemid 39071477)
2. Zitzmann M, Faber S, Nieschlag E: Association of specific symptoms and metabolic risks with serum testosterone in older men. J. Clin. Endocrinol. Metab. 91, 4335-4343 (2006). (Pubitemid 44833407)
3. Zitzmann M: Mechanisms of disease: pharmacogenetics of testosterone therapy in hypogonadal men. Nat. Clin. Pract. Urol. 4, 161-166 (2007).
4. Canale D, Caglieresi C, Moschini C et al.: Androgen receptor polymorphism (CAG repeats) and androgenicity. Clin. Endocrinol. (Oxf.) 63, 356-361 (2005). ■■ Key publication in the field, opening the pathway to new understanding of androgen action. (Pubitemid 41233456)
5. Zitzmann M, Nieschlag E: Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J. Clin. Endocrinol. Metab. 92, 3844-3853 (2007). (Pubitemid 47607632)
6. Chang C, Kokontis J, Liao S: Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. Proc. Natl. Acad. Sci. USA 85, 7211-7215 (1988). (Pubitemid 18241855)
7. Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, French FS: Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr. Rev. 16, 271-321 (1995).
8. Heinlein CA, Chang C: Androgen receptor (AR) coregulators: an overview. Endocr. Rev. 23, 175-200 (2002). ■■ Key publication in the field, opening the pathway to new understanding of androgen action.
9. Hiort O, Sinnecker GHG, Holterhus PM, Nitsche EM, Kruse K: The clinical and molecular spectrum of androgen insensitivity. Am. J. Med. Genet. 63, 218-222 (1996) (Pubitemid 26147446)
10. Meschede D, Behre HM, Nieschlag E: Disorders of androgen target organs. In: Andrology: male reproductive health and dysfunction, 2nd edition. Nieschlag E, Behre HM (Eds). Springer Heidelberg, Germany, 223-229 (2000).
11. Albertelli MA, Scheller A, Brogley M, Robins DM: Replacing the mouse androgen receptor with human alleles demonstrates glutamine tract length-dependent effects on physiology and tumorigenesis in mice. Mol. Endocrinol. 20, 1248-1260 (2006). ■■ Key publication in the field, opening the pathway to new understanding of androgen action. (Pubitemid 43801229)
12. Coutinho-Camillo CM, Miracca EC, dos Santos ML, Salaorni S, Sarkis AS, Nagai MA: Identification of differentially expressed genes in prostatic epithelium in relation to androgen receptor CAG repeat length. Int. J. Biol. Markers 21, 96-105 (2006).
13. Zeegers MP, Kiemeney LA, Nieder AM, Ostrer H: How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? Cancer Epidemiol. Biomarkers Prev. 13, 1765-1771 (2004).
14. Hsiao PW, Lin DL, Nakao R, Chang C: The linkage of Kennedy's neuron disease to ARA24 the first identified androgen receptor polyglutamine region-associated coactivator. J. Biol. Chem. 274, 20229-20234 (1999). (Pubitemid 129519494)
15. Irvine RA, Ma H, Yu MC, Ross RK, Stallcup MR, Coetzee GA: Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum. Mol. Gen. 9, 267-274 (2002). (Pubitemid 30052750)
16. Giovannucci E, Stampfer MJ, Chan A et al.: CAG repeat within the androgen receptor gene and incidence of surgery for benign prostatic hyperplasia in U.S. physicians. Prostate 39, 130-134 (1999). (Pubitemid 29194285)
17. Giovannucci E, Platz EA, Stampfer MJ et al.: The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. Urology 53, 121-125 (1999). ■■ Key publication in the field, opening the pathway to new understanding of androgen action. (Pubitemid 29016626)
18. Mitsumori K, Terai A, Oka H et al.: Androgen receptor CAG repeat length polymorphism in benign prostatic hyperplasia (BPH): correlation with adenoma growth. Prostate 41, 253-257 (1999).
19. Zitzmann M, Brune M, Kornmann B et al.: The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity. J. Clin. Endocrinol. Metab. 86, 4867-4873 (2001). (Pubitemid 33020534)
20. Zitzmann M, Brune M, Kornmann B, Gromoll J, Nieschlag E: The CAG repeat polymorphism in the androgen receptor gene affects bone density and bone metabolism in healthy males. Clin. Endocrinol. (Oxf.) 55, 649-657 (2001). (Pubitemid 34204448)
21. Yaffe K, Edwards ER, Lui LY, Zmuda JM, Ferrell RE, Cauley JA: Androgen receptor CAG repeat polymorphism is associated with cognitive function in older men. Biol. Psychiatry 54, 943-946 (2003). (Pubitemid 37311358)
22. Seidman SN, Araujo AB, Roose SP, McKinlay JB: Testosterone level, androgen receptor polymorphism, and depressive symptoms in middle-aged men. Biol. Psychiatry 50, 371-376 (2001).
23. Zitzmann M, Nieschlag E: The CAG repeat polymorphism within the androgen receptor gene and maleness. Int. J. Androl. 26, 76-83 (2003). (Pubitemid 36408236)
24. Nicolaiew N, Cancel-Tassin G, Azzouzi AR et al.: Association between estrogen and androgen receptor genes and prostate cancer risk. Eur. J. Endocrinol. 160(1), 101-106 (2008).
25. Hare L, Bernard P, Sánchez FJ et al.: Androgen receptor repeat length polymorphism associated with male-to-female transsexualism. Biol. Psychiatry 65(1), 93-96 (2008).
26. Pang Y, He C, Liu Y et al.: Combination of short CAG and GGN repeats in the androgen receptor gene is associated with acne risk in North East China. J. Eur. Acad. Dermatol. Venereol. 22(12), 1445-1451 (2008).
27. Lappalainen S, Utriainen P, Kuulasmaa T, Voutilainen R, Jääskeläinen J: Androgen receptor gene CAG repeat polymorphism and X-chromosome inactivation in children with premature adrenarche. J. Clin. Endocrinol. Metab. 93, 1304-1309 (2008).
28. Lenz B, Jacob C, Frieling H et al.: Polymorphism of the long polyglutamine tract in the human androgen receptor influences craving of men in alcohol withdrawal. Psychoneuroendocrinology 34(7), 968-971 (2009).
29. Yang Z, Yu H, Cheng B et al.: Relationship between the CAG repeat polymorphism in the androgen receptor gene and acne in the Han ethnic group. Dermatology (2009) (Epub ahead of print).
30. Härkönen K, Huhtaniemi I, Mäkinen J et al.: The polymorphic androgen receptor gene CAG repeat, pituitary-testicular function and andropausal symptoms in ageing men. Int. J. Androl. 26, 187-194 (2003). (Pubitemid 36718211)
31. Su QR, Su LY, Su HR et al.: Polymorphisms of androgen receptor gene in childhood and adolescent males with first-onset major depressive disorder and association with related symptomatology. Int. J. Neurosci. 117, 903-917 (2007).
32. Colangelo LA, Sharp L, Kopp P et al.: Total testosterone, androgen receptor polymorphism, and depressive symptoms in young black and white men: the CARDIA Male Hormone Study. Psychoneuroendocrinology 32, 951-958 (2007). (Pubitemid 350086809)
33. Zitzmann M, Gromoll J, von Eckardstein A, Nieschlag E: The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men. Diabetologia 46, 31-39 (2003). (Pubitemid 36237744)
34. Stanworth R, Kapoor D, Channer K, Jones T: Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes. Eur. J. Endocrinol. 159(6), 739-746 (2008).
35. Rajender S, Gupta NJ, Chakravarty B, Singh L, Thangaraj K: Androgen insensitivity syndrome: do trinucleotide repeats in androgen receptor gene have any role? Asian J. Androl. 10, 616-624 (2008). (Pubitemid 351865768)
36. Davis-Dao CA, Tuazon ED, Sokol RZ, Cortessis VK: Male infertility and variation in CAG repeat length in the androgen receptor gene: a meta-analysis. J. Clin. Endocrinol. Metab. 92, 4319-4326 (2007). ■■ Key publication in the field, opening the pathway to new understanding of androgen action.
37. Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E: X-chromosome inactivation patterns and androgen receptor functionality influence phenotype and social characteristics as well as pharmacogenetics of testosterone therapy in Klinefelter patients. J. Clin. Endocrinol. Metab. 89, 6208-6217 (2004). ■■ Key publication in the field, opening the pathway to new understanding of androgen action. (Pubitemid 39628435)
38. Zinn AR, Ramos P, Elder FF, Kowal K, Samango-Sprouse C, Ross JL: Androgen receptor CAGn repeat length influences phenotype of 47,XXY (Klinefelter) syndrome. J. Clin. Endocrinol. Metab. 90, 5041-5046 (2005). (Pubitemid 41262252)
39. Wikstrom AM, Painter JN, Raivio T, Aittomaki K, Dunkel L: Genetic features of the X chromosome affect pubertal development and testicular degeneration in adolescent boys with Klinefelter syndrome. Clin. Endocrinol. (Oxf.) 65, 92-97 (2006). (Pubitemid 43911686)
40. Vorona E, Zitzmann M, Gromoll J, Schuring AN, Nieschlag E: Clinical, endocrinologic and epigenetic features of the 46, XX male syndrome compared to 47,XXY Klinefelter patients. J. Clin. Endocrinol. Metab. 92, 3458-3465 (2007). (Pubitemid 47435320)
41. Page ST, Kupelian V, Bremner WJ, McKinlay JB: The androgen receptor gene CAG repeat polymorphism does not predict increased risk of heart disease: longitudinal results from the Massachusetts Male Ageing Study. Clin. Endocrinol. (Oxf.) 65, 333-339 (2006). (Pubitemid 44244922)
42. Huhtaniemi IT, Pye SR, Limer KL et al.: Increased estrogen rather than decreased androgen action is associated with longer androgen receptor CAG repeats. J. Clin. Endocrinol. Metab. 94(1), 277-284 (2008).
43. Limer KL, Pye SR, Thomson W et al.: Genetic variation in sex hormone genes influences heel ultrasound parameters in middle aged and elderly men: results from the European male ageing study (EMAS). J. Bone Miner. Res. 24(2), 314-323 (2008).
44. Wang C, Nieschlag E, Swerdloff R et al.: Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur. J. Endocrinol. 159, 507-514 (2008).
45. Shabsigh R, Arver S, Channer KS et al.: The triad of erectile dysfunction, hypogonadism and the metabolic syndrome. Int. J. Clin. Pract. 62, 791-798 (2008).
46. Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E: Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study. J. Clin. Endocrinol. Metab. 88, 2049-2054 (2003). ■■ Key publication in the field, opening the pathway to new understanding of androgen action. (Pubitemid 36549876)
47. von Eckardstein S, Syska A, Gromoll J, Kamischke A, Simoni M, Nieschlag E: Inverse correlation between sperm concentration and number of androgen receptor CAG repeats in normal men. J. Clin. Endocr. Metab. 86, 2585-2590 (2001). (Pubitemid 32545710)
48. Li JW, Gu YQ: Predictors for partial suppression of spermatogenesis of hormonal male contraception. Asian J. Androl. 10, 723-730 (2008).
49. Yu B, Handelsman DJ: Pharmacogenetic polymorphisms of the AR and metabolism and susceptibility to hormone-induced azoospermia. J. Clin. Endocrinol. Metab. 86, 4406-4411 (2001). (Pubitemid 32848566)
50. Wakisaka N, Taira Y, Ishikawa M et al.: Effectiveness of finasteride on patients with male pattern baldness who have different androgen receptor gene polymorphism. J. Investig. Dermatol. Symp. Proc. 10, 293-294 (2005).
51. Ong KK, de Zegher F, López-Bermejo A, Dunger DB, Ibáñez L: Flutamide metformin for post-menarcheal girls with preclinical ovarian androgen excess: evidence for differential response by androgen receptor genotype. Eur. J. Endocrinol. 157, 661-668 (2007). (Pubitemid 350187384)
52. Bhasin S, Woodhouse L, Casaburi R et al.: Testosterone dose-response relationships in healthy young men. Am. J. Physiol. Endocrinol. Metab. 281, 1172-1181 (2001). ■■ Key publication in the field, opening the pathway to new understanding of androgen action. (Pubitemid 33775060)
53. Morgentaler A, Traish AM: Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur. Urol. (2008) (Epub ahead of print). ■■ Key publication in the field, opening the pathway to new understanding of androgen action.